Stephen Annest
Vascular Surgery · Denver, CONPI 1093792590
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,665 of the $28,248 with a category attached, or 66.1%. Johnson & Johnson accounts for 79.4% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2022 at $18,834 and has fallen 88.3% since, to $2,206 in 2025.
Across 116 payments — averaging $243.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$22K
- Angiodynamics, Inc.$3K
- Medtronic$2K
- Veryan Medical Incorporated$317
- Lemaitre Vascular, Inc.$259
- Abbott$196
- plus $659 from 20 others
What the payments were for
- Speaking & faculty fees$18,66566%
- Travel & lodging$3,87014%
- Food & beverage$2,95210%
- Education$460%
- Other$2,71510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 47 | $22,418 |
| Angiodynamics, Inc. | 4 | $2,766 |
| Medtronic(2 entities) | 22 | $1,632 |
| Veryan Medical Incorporated | 2 | $317 |
| Lemaitre Vascular, Inc. | 8 | $259 |
| Abbott | 2 | $196 |
| Inari Medical, Inc. | 6 | $91 |
| Smith+Nephew | 3 | $75 |
| Baxter Healthcare | 2 | $69 |
| Boston Scientific | 2 | $52 |
| Philips North America LLC | 1 | $40 |
| Cvrx, Inc. | 1 | $39 |
| Medline Industries LP | 2 | $33 |
| Avanos Medical | 1 | $32 |
| Cardiovascular Systems Inc. | 2 | $29 |
| Pfizer | 1 | $22 |
| Cardinal Health 200 LLC | 1 | $21 |
| Shockwave Medical, Inc | 1 | $20 |
| Silk Road Medical, Inc. | 1 | $19 |
| Dilon Technologies, Inc. | 1 | $19 |
| Integra Lifesciences Corporation | 1 | $19 |
| Centerline Biomedical Inc. | 1 | $19 |
| Ossur Americas, Inc. | 1 | $18 |
| Acera Surgical, Inc. | 1 | $15 |
| Acell, Inc. | 1 | $14 |
| Baudax Bio Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$21,560
- Auryon Laser System 100-120 Vac$2,715
- HawkOne$957
- BioMimics$260
- Omnilink Elite vascular stent system$135
- IN.PACT Admiral$134
How this compares
$28,248 in reported general payments places this provider in the 85th percentile of 66 vascular surgery providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 17 | $16,178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $22,418 | $16,17817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 66 vascular surgery providers in Colorado.
Other vascular surgery in Denver
- Brandon Roy-GarlandDenver$190K
- Lisa BennettDenver$30K
- Omar MubarakDenver$22K
- Alexander LeungDenver$21K
- Alan SynnDenver$16K
- Charles FoxDenver$11K
- Timothy ChiltonDenver$10K
- Barbara MelendezDenver$7K
- Rebecca UrDenver$4K
- Eric WeinsteinDenver$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.